condition: Type I has low levels of FX antigen and activity. Type II has low coagulant activity but normal or borderline FX antigen levels. The FX (F10) gene is found on chromosome 13q34. Heterogeneous mutations have been described in FX deficient patients. Treatment There are several treatments available for bleeding due to factor X deficiency. A specific FX concentrate was not available . Prothrombin complex concentrate (PCC) supplies FX with a risk of thrombosis. Fresh frozen plasma (FFP): This is relatively inexpensive and readily available. While effective this treatment carries a risk of blood-borne viruses and fluid overload. If vitamin K levels are low, vitamin K can be supplied orally or parenterally. Treatment of FX deficiency in amyloidosis may be more complex and involve surgery (splenectomy) and chemotherapy. History The condition was described independently in the 1950s. Telfer and coworkers described a female patient named Prower in 1956 and Hougie and coworker described a male patient named Stuart in 1957. When experiments showed that serum from these two patients lacked the same factor, these two patients were the first people identified with FX deficiency and the factor was called Stuart-Prower factor, later factor X. References External links Bleeding Coagulopathies